Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05732974

A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse — MIRACLE  

Non-small Cell Lung Cancer Stage IIIA Clinical Trial

Official title:
A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse

Clinical Trial Summary

Early-stage non small cell lung cancer represents 20-30% of all non small cell lung cancer and is characterized by a high survival probability after surgical resection. However, considering stage IA-IIIA non small cell lung cancer, a relapse rate of about 50% is observed, with a different survival probability on the basis of tumor node metastasis status, although patients within the same tumor node metastasis stage exhibit wide variations in recurrence rate. There are currently no validated prognostic biomarkers able to identify patients with a high risk of relapse.

Clinical Trial Description

This study will use data from an already available cohort of patients enrolled in the Resting study (a project funded by TRANSCAN in 2018) as a training set and data from a new concurrent cohort as validation set. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05732974
Study type Observational
Source University Hospital, Toulouse
Contact Julien MAZIERES, MD, PhD
Phone 0567771837
Email mazieres.j@chu-toulouse.fr
Status Recruiting
Phase
Start date March 30, 2023
Completion date October 30, 2026
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04455594 - Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC Phase 2
Recruiting NCT02977169 - To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer Phase 2
Terminated NCT02974426 - To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer Phase 3
Completed NCT01991418 - Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC) N/A
Recruiting NCT01410214 - Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations Phase 2
Recruiting NCT01926483 - Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection Phase 2
Recruiting NCT04716946 - Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy Phase 2
Recruiting NCT06268613 - A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy Phase 1